Erlotinib–silk fibroin nanoparticles in inhibiting tumor

Qiu, Hao; Wang, Jiamin; Sun, Zheng

doi:10.1007/s00289-019-02946-1

Cited by 6 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DXL-loaded SF nanoparticles were prepared by a nanoprecipitation technique as described previously [ 32 ]. Drug loaded SF-NPs were prepared at different ratios of drug/SF ranging from 1:1 to 1:5 ( w / w ) ( Table 1 ).…”

Section: Methodsmentioning

confidence: 99%

“…Several types of silk-fibroin-based drug delivery systems have been introduced in the pharmaceutical field including, films, hydrogels, lyophilized sponges, nanofibers as well as micro- and nanoparticles [ 27 , 28 , 29 , 30 ]. SF-based nanoparticles as drug delivery vehicles, in particular, have attracted a lot of interest because of their high drug loading ability, tunable drug release properties, and easy preparation [ 31 , 32 ]. In addition, by virtue of their versatile chemical structure, SF-based nanoparticles hold the ability to encapsulate both hydrophilic and hydrophobic drugs.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enhanced Cytotoxic Activity of Docetaxel-Loaded Silk Fibroin Nanoparticles against Breast Cancer Cells

Saqr

Wani²,

Gangadharappa

et al. 2021

Polymers

View full text Add to dashboard Cite

Despite decades of research, breast cancer therapy remains a great challenge. Docetaxel is an antimicrotubule agent that is effectively used for the treatment of breast cancer. However, its clinical use is significantly hampered by its low water solubility and systemic toxicity. The current study was designed to prepare docetaxel (DXL)-loaded silk-fibroin-based nanoparticles (SF-NPs) and to screen their potential antitumor activity against breast cancer cell lines. DXL-loaded SF-NPs were prepared using a nanoprecipitation technique and were evaluated for particle size, zeta potential, entrapment efficiency, and in vitro release profile. In addition, DXL-loaded SF-NPs were screened for in vitro cytotoxicity, cellular uptake, and apoptotic potential against MCF-7 and MDA-MB-231 breast cancer cell lines. The prepared DXL-loaded SF-NPs were 178 to 198 nm in diameter with a net negative surface charge and entrapment efficiency ranging from 56% to 72%. In vitro release studies exhibited a biphasic release profile of DXL from SF-NPs with sustained drug release for 72 h. In vitro cell studies revealed that entrapment of DXL within SF-NPs significantly improved cytotoxic potential against breast cancer cell lines, compared to the free drug, and enhanced cellular uptake of DXL by breast cancer cells. Furthermore, the accumulation in the G2/M phase was significantly higher in cells treated with DXL-loaded SF-NPs than in cells treated with free DXL. Collectively, the superior antitumor activities of DXL-loaded SF-NPs against breast cancer cells, compared to free DXL, could be ascribed to improved apoptosis and cell cycle arrest. Our results highlighted the feasibility of using silk fibroin nanoparticles as a nontoxic biocompatible delivery vehicle for enhanced therapeutic outcomes in breast cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Enhanced Cytotoxic Activity of Docetaxel-Loaded Silk Fibroin Nanoparticles against Breast Cancer Cells

Saqr

Wani²,

Gangadharappa

et al. 2021

Polymers

View full text Add to dashboard Cite

show abstract

“…Several types of SF-based drug delivery systems have been introduced in the pharmaceutical field including; films, hydrogels, lyophilized sponges, nanofibers as well as micro and nanoparticles (Qi et al, 2017 ; Wang et al, 2010 ; Terada et al, 2016 ; Chirila et al, 2017 ). Among them, SF nanoparticles have been studied the most, particularly for anticancer drugs (Montalbán et al, 2018 ; Tian et al, 2014 ; Li et al, 2020 ). Generally, nanoparticles based systems are well-recognized to improve drug accumulation within tumor tissue via the enhanced permeation and retention (EPR) effect (Greish, 2010 ).…”

Section: Introductionmentioning

confidence: 99%

Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer

Moin

Wani²,

Osmani

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

Silk fibroin (SF) is a natural polymeric biomaterial that is widely adopted for the preparation of drug delivery systems. Herein, we aimed to fabricate and characterize SF nanoparticles loaded with the selective estrogen receptor modulator; tamoxifen citrate (TC-SF-NPs) and to assess their in vitro efficacy against breast cancer cell lines (MCF-7 and MDA-MB-231). TC-loaded SF-NPs were characterized for particle size, morphology, entrapment efficiency, and release profile. In addition, we examined the in vitro cytotoxicity of TC-SF-NPs against human breast cancer cell lines and evaluated the anticancer potential of TC-SF-NPs through apoptosis assay and cell cycle analysis. Drug-loaded SF-NPs showed an average particle size of 186.1 ± 5.9 nm and entrapment efficiency of 79.08%. Scanning electron microscopy (SEM) showed the nanoparticles had a spherical morphology with smooth surface. Tamoxifen release from SF-NPs exhibited a biphasic release profile with an initial burst release within the first 6 h and sustained release for 48 h. TC-SF-NPs exerted a dose-dependent cytotoxic effect against breast cancer cell lines. In addition, flow cytometry analysis revealed that cells accumulate in G 0 /G 1 phase, with a concomitant reduction of S- and G 2 -M-phase cells upon treatment with TC-SF-NPs. Consequently, the potent anticancer activities of TC-SF-NPs against breast cancer cells were mainly attributed to the induction of apoptosis and cell cycle arrest. Our results indicate that SF nanoparticles may represent an attractive nontoxic nanocarrier for the delivery of anticancer drugs.

show abstract

“…Today, there are several anticancer drug preparations formulated with different nanocarriers in the market and successful results are obtained in the clinic [7,8] with these nanomedicines and their follow-on products; nanosimilars. In the meantime, new formulation strategies have been developed for ERL to improve efficacy and to reduce side effects [9][10][11][12][13]. There are clinical trials at various stages focusing on ERL therapeutic indication as well as formulation.…”

Section: Introductionmentioning

confidence: 99%

Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver

Varan

Akkın

Demirtürk

et al. 2020

Journal of Drug Targeting

View full text Add to dashboard Cite

Erlotinib (ERL), a tyrosine kinase inhibitor approved for therapeutic use in nonsmall cell lung cancer is further researched for eventual liver cancer treatment.However, conventional ERL has important bioavailability problems resulting from oral administration, poor solubility and gastrointestinal degradation into inactive metabolites. Alternative administration routes and nanoparticulate drug delivery systems are studied to prevent or reduce these drawbacks. In this study, ERL-loaded CD nanosphere and nanocapsule formulations capable of cholesterol depletion in resistant cancer cells were evaluated for ERL delivery. Drug loading and release profile depended largely on the surface charge of nanoparticles.Antiproliferative activity data obtained from 2D and 3D cell culture models demonstrated that polycationic βCD nanocapsules were the most effective formulation for ERL delivery to lung and liver cancer cells. 3D tumor uptake studies further revealed that nanocapsule formulations penetrated deeper into the tumor through the multilayered cells. Furthermore, all formulations were able to extract membrane cholesterol from lung and liver cancer cell lines, indicating induction of apoptosis and overcoming drug resistance. In conclusion, given their tumoral penetration and cell membrane cholesterol depletion abilities, amphiphilic CD nanocapsules emerge as promising alternatives to improve the safety and efficiency of ERL treatment of both liver and lung tumors.

show abstract

Erlotinib–silk fibroin nanoparticles in inhibiting tumor

Cited by 6 publications

References 28 publications

Enhanced Cytotoxic Activity of Docetaxel-Loaded Silk Fibroin Nanoparticles against Breast Cancer Cells

Enhanced Cytotoxic Activity of Docetaxel-Loaded Silk Fibroin Nanoparticles against Breast Cancer Cells

Formulation, characterization, and cellular toxicity assessment of tamoxifen-loaded silk fibroin nanoparticles in breast cancer

Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver

Contact Info

Product

Resources

About